. Author manuscript; available in PMC: 2014 Jun 5.

Published in final edited form as: Am J Gastroenterol. 2014 Jan 14;109(3):357–368. doi: 10.1038/ajg.2013.443

Table A2.

Assessment of additive interaction between Helicobacter pylori and weekly use (or more) of H2RA or PPI on BE

Variable	Estimate (s.e.)	Wald χ² (P value)^a
Unadjusted
H. pylori	–0.05 (0.04)	1.93 (0.17)
Use of H2RA or PPI	0.43 (0.04)	112.5 (<0.0001)
Interaction between H. pylori and H2RA/PPI use	–0.20 (0.09)	5.11 (0.02)
Adjusted^a
H. pylori	–0.03 (0.04)	0.58 (0.44)
Use of H2RA or PPI	0.39 (0.04)	84.3 (<0.0001)
Interaction between H. pylori and H2RA/PPI use	–0.15 (0.09)	3.19 (0.07)

BE, Barrett's esophagus; H2RA, H2 receptor antagonist; PPI, proton pump inhibitor.

Controlling for age and non-Hispanic white race.